New IP application for Acrux

Company News

Acrux (ASX:ACR) says it has filed a new provisional patent application covering its pipeline product ACR-065 targeting fungal infection of the nail bed in toes and fingers (onychomycosis).

The company said lodgment of the new patent application is an important step in progressing its’ product development pipeline, including onychomycosis.

"ACR-065 is an improved formulation of the most effective and leading topically applied treatment on the market for onychomycosis, Jublia, which contains the antifungal agent efinaconazole. Acrux is progressing development and expects to initiate clinical trials in the second half of 2017," it said.